Rose SL. Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness. J Law Med Ethics 2013;41:680–687.
McCoy MSCarniol MChockley K. Conflicts of interest for patient-advocacy organizations. N Engl J Med 2017;376:880–885.
Giving USA. See the numbers—Giving USA 2019 infographic. Available at: https://givingusa.org/. Accessed June 20 2019.
Abola MVPrasad V. Industry funding of cancer patient advocacy organizations. Mayo Clin Proc 2016;91:1668–1670.
Rothman SMRaveis VHFriedman A. Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices. Am J Public Health 2011;101:602–609.
Clemence MGilby NShah J. Wellcome Trust Monitor Wave 2: tracking public views on science biomedical research and science education. London UK: Wellcome Trust; May 2013. Available at: https://wellcome.ac.uk/sites/default/files/monitor-wave2-full-wellcome-may13.pdf. Accessed June 20 2019.
Shah KKSussex JHernandez-Villafuerte K. Government and charity funding of cancer research: public preferences and choices. Health Res Policy Syst 2015;13:38.
Noone AMHowlader NKrapcho M. SEER Cancer Statistics Review 1975-2015 National Cancer Institute. Bethesda MD. Available at: https://seer.cancer.gov/csr/1975_2015/ based on November 2017 SEER data submission posted to the SEER web site April 2018. Accessed March 13 2019.
Arias E. United States Life Tables 2011. Natl Vital Stat Rep 2015;64:1–63.
Fattovich GStroffolini TZagni I. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(Suppl):S35–50.
Prabhu AObi KORubenstein JH. The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: a meta-analysis. Am J Gastroenterol 2014;109:822–827.
Freedman NDAbnet CCCaporaso NE. Impact of changing US cigarette smoking patterns on incident cancer: risks of 20 smoking-related cancers among the women and men of the NIH-AARP cohort. Int J Epidemiol 2016;45:846–856.
Harvey JAStrahilevitz MA. The power of pink: cause-related marketing and the impact on breast cancer. J Am Coll Radiol 2009;6:26–32.
Carter AJNguyen CN. A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding. BMC Public Health 2012;12:526.
Burnet NGJefferies SJBenson RJ. Years of life lost (YLL) from cancer is an important measure of population burden—and should be considered when allocating research funds. Br J Cancer 2005;92:241–245.
Carter AJDelarosa BHur H. An analysis of discrepancies between United Kingdom cancer research funding and societal burden and a comparison to previous and United States values. Health Res Policy Syst 2015;13:62.